Table 3. Success factors in Iranian coronavirus disease 2019 vaccines (author’s conclusion based-on interviews and policy reports).
| Success factor | Product | |||||
|---|---|---|---|---|---|---|
| COVIran Barekat | SPikoGen | PastoCovac | Razi Cov Pars | Noora | FakhraVac | |
| Internal factors | ||||||
| Internal networking within Iran | ○ | ○ | ||||
| International technological collaboration | ○ | ○ | ○ | |||
| Private ownership of the developer | ○ | |||||
| Access to finance mainly from inside resources | ○ | ○ | ○ | ○ | ○ | ○ |
| Accumulation of experience and tacit knowledge related to vaccine development | ○ | ○ | ○ | |||
| External factors | ||||||
| Well-known brand and popularity | ○ | ○ | ○ | |||
| Speed in issuing permits and administrative processes | ○ | |||||
| Large unvaccinated population of Iran during the clinical trials of vaccines | ○ | ○ | ○ | |||
| Receive subsidies for importing raw materials and vaccine production equipment | ○ | ○ | ○ | ○ | ||